Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 3, 2006, Pages 1336-1347

  Štěrba, Martin ^a   Popelová, Olga ^a   Šimůnek, Tomáš ^b   Mazurová, Yvona ^a   Potáčová, Anna ^a   Adamcová, Michaela ^a   Kaiserová, Helena ^b   Poňka, Přemysl ^c   Geršl, Vladimír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; IRON CHELATING AGENT; O 108; PYRIDOXAL 2 CHLOROBENZOYL HYDRAZONE; TROPONIN T; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CARDIOTOXICITY; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART PROTECTION; HEMATOLOGICAL PARAMETERS; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MORPHOLOGY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; WEIGHT CHANGE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD PRESSURE; BODY WEIGHT; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CELL DIVISION; CHINCHILLA; DAUNORUBICIN; ELECTROCARDIOGRAPHY; HEART DISEASES; HEART RATE; HL-60 CELLS; HUMANS; HYDRAZONES; IRON CHELATING AGENTS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PYRIDOXAL; RABBITS; STROKE VOLUME; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 33751187356     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111468     Document Type: Article

References (48)

1. Abou-El-Hassan MA, Rabelink MJ, van der Vijgh WJ, Bast A, and Hoeben RC (2003) A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro. Br J Cancer 89:2140-2146.
2. Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y, and Gersl V (2005) Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 4:457-472.
3. Barnabe N, Zastre JA, Venkataram S, and Hasinoff BB (2002) Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 33:266-275.
4. Baker E, Richardson D, Gross S, and Ponka P (1992) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15:492-501.
5. Berthiaume JM, Oliveira PJ, Fariss MW, and Wallace KB (2005) Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 5:257-267.
6. Bruynzeel AM, Mul PP, Berkhof J, Bast A, Niessen HW, and van der Vijgh WJ (2006) The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemother Pharmacol 58:699-702.
7. Cvetkovic RS and Scott LJ (2005) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005-1024.
8. Cusack BJ, Young SP, and Olson RD (1995) Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother Pharmacol 35:213-218.
9. Fisher PW, Salloum F, Das A, Hyder H, and Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601-1610.
10. Gersl V and Hrdina R (1994) Noninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits. Sbornik vědeckých praci Lékařské fakulty Karlovy University v Hradci Králové 37:49-55.
11. Gersl V, Sterba M, Simunek T, Kaplanova J, Adamcova M, Klimtova I, Cermakova E, and Mazurová Y (2004) Study of the effects of PIH in daunorubicin-induced cardiomopathy in rabbits. Clin Exp Pharmacol Physiol 31:A197.
12. Hasinoff BB, Hellmann K, Herman EH, and Ferrans VJ (1998) Chem, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28.
13. Hasinoff BB, Patel D, and Wu X (2003) The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med 35:1469-1479.
14. Herman EH and Ferrans VJ (1986) Pretreatment with ICRF-187 provides longlasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol 16:102-106.
15. Herman EH, Ferrans VJ, Myers CE, and Van Vleet JF (1985) Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res 45:276-281.
16. Herman EH, Zhang J, and Ferrans VJ (1994) Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 35:93-100.
17. Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, and Adamcova M (2000) Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove) 43:75-82.
18. Iliskovic N, Hasinoff BB, Malisza KL, Li T, Danelisen I, and Singal PK (1999) Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem 196:43-49.
19. Kalinowski DS and Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547-583.
20. Klimtova I, Simunek T, Mazurova Y, Hrdina R, Gersl V, and Adamcova M (2002) Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. Hum Exp Toxicol 21:649-657.
21. Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, and Ponka P (2006) HPLC determination of novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 838:107-112.
22. Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, and Ponka P (2005) Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J Sep Sci 28:1300-1306.
23. Kovarikova P, Mokry M, Klimes J, and Vavrova K (2004) Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron chelates. J Sep Sci 27:1503-1510.
24. Kwok JC and Richardson DR (2003) Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 63:849-861.
25. Kwok JC and Richardson DR (2004) Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol Pharmacol 65:181-195.
26. Le NT and Richardson DR (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104:2967-2975.
27. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, and Ali MK (1982) Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann NY Acad Sci 393:411-418.
28. Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, and Hershko C (2003) Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 101:4172-4179.
29. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, and Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815.
30. Marian AJ (2005) On mice, rabbits, and human heart failure. Circulation 111:2276-2279.
31. Marty M, Espie M, Llombart A, Monnier A, Rapoport BL, and Stahalova V (2006) Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 17:614-622.
32. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
33. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, Doroshow J, and Epstein S (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 10:53-55.
34. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, and Wallace KB (2004) Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200:159-168.
35. Ponka P, Borova J, Neuwirt J, and Fuchs O (1979) Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97:317-321.
36. Richardson DR, Tran EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
37. Sterba M, Simunek T, Mazurova Y, Adamcova M, Popelova O, Kaplanova J, Ponka P, and Gersl V (2005) Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Hum Exp Toxicol 24:581-589.
38. Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, et al. (2005a) SIH-a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 39:345-354.
39. Simunek T, Klimtova I, Kaplanova J, Mazurova Y, Adamcova M, Sterba M, Hrdina R, and Gersl V (2004) Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur J Heart Fail 6:377-387.
40. Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, Hrdina R, Gersl V, and Ponka P (2005b) Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol Res 51:223-231.
41. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, and Meyers M (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127.
42. Swain SM and Vici P (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 130:1-7.
43. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332.
44. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, and Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717.
45. Wu X and Hasinoff BB (2005) The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 16:93-99.
46. Xu X, Persson HL, and Richardson DR (2005) Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68:261-271.
47. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458.
48. Yee GC (2005) Oncologic disorders, in Pharmacotherapy: A Pathophysiologic Approach (DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey MI eds) pp 2279-2558, The McGraw-Hill Companies, New York.